tbuckley/cabot-search huggingface dataset:
What can we learn in drug allergy management from World Health Organization's international classifications?
Authors: L. K. Tanno, M. J. Torres, M. Castells, P. Demoly
Journal: Allergy (2017)

Drug hypersensitivity reactions (DHRs) represent growing health problem worldwide, affecting more than 7% of the general population, and represent an important public health problem. However, knowledge in DHRs morbidity and mortality epidemiological data is still not optimal and international comparable standards remain poorly accessed. Institutional databases worldwide increasingly use the WHO International Classification of Diseases (ICD) system to classify diagnoses, health services utilization, and death data. The misclassification of disorders in the ICD system contributes to a lack of ascertainment and recognition of their importance for healthcare planning and resource allocation. It also hampers clinical practice and prevention actions. To further inform the allergy community and to ensure that the revision process is transparent as advised in the WHO ICD-11 revision agenda, we report the advances and use of the pioneering "Drug hypersensitivity" subsection of ICD-11 and implementation in the WHO International Classification of Health Interventions (ICHI). The new classification addressed to DHRs will enable the collection of more accurate epidemiological data to support quality management of patients with drug allergies and better facilitate healthcare planning and decision-making and public health measures to prevent and reduce the morbidity and mortality attributable to DHRs.
SURG-25. A NOVEL BIO-IMPEDANCE SPECTROSCOPY SYSTEM REAL-TIME INTRAOPERATIVELY DISCRIMINATES GLIOBLASTOMA FROM BRAIN TISSUE IN MICE
Authors: Yuhui Zhang, Shoupei Xu, Weijie Min, Linyong Shen, Yanan Zhang, Zhijian Yue
Journal: Neuro-Oncology (2017)

"Tumor boundary" is difficult to be identified during glioblastoma (GBM) resection. Based on the bio-impedance difference between GBM and brain tissue, a novel bio-impedance spectroscopy system was developed to distinguish tumor from brain tissue, and detect the "tumor boundary" for the improvement of the effectiveness and safety during operation. To study this, the intracranial GBM model in mice was established. A tetrapolar bio-impedance spectroscopy-based measuring box system was invented to measure tissue impedance. Tumor and brain tissue were collected from mice, and respectively loaded into the box system for impedance measurement. The bio-impedance measurements were performed under small alternating current signal in the frequency from 1Hz to 1MHz and then analyzed particularly from 20Hz to 250K Hz. The spectroscopic analysis results revealed distinctive impedance difference between GBM and brain tissue in low and middle frequency zone (P<0.01). Furthermore, another novel impedance spectroscopy-based measurement system was design and invented to measure tissue impedance in vivo. The tumor and brain tissue were intactly measured with the detector put on the surface of the tissue. The spectroscopic analysis results showed distinctive impedance difference between GBM and brain tissue in the frequency from 100K Hz to 250K Hz (P<0.01). The slope index of the impedance curve from 100K Hz to 250K Hz was calculated. It was increased by 352.57% with U87 tumor compared to brain tissue, and 150.23% with C6 tumor compared to brain tissue (P<0.05). Although further research is needed for the future application in clinic, the novel bio-impedance spectroscopy-based measurement system provides an alternative method to discriminate GBM from brain tissue for the detection of the "tumor boundary".
Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial
Authors: Heather A Wakelee, Suzanne E Dahlberg, Steven M Keller, William J Tester, David R Gandara, Stephen L Graziano, Alex A Adjei, Natasha B Leighl, Seena C Aisner, Jan M Rothman, Jyoti D Patel, Mark D Sborov, Sean R McDermott, Roman Perez-Soler, Anne M Traynor, Charles Butts, Tracey Evans, Atif Shafqat, Andrew E Chapman, Samer S Kasbari, Leora Horn, Suresh S Ramalingam, Joan H Schiller
Journal: The Lancet Oncology (2017)
P1.02-035 Human Papillomavirus Infection in Lung Squamous Cell Carcinoma and Correlation to p16 INK4a Expression from an Argentine Population
Authors: M.M. García Falcone, M. Cuello, A.J. Garcia, G. Recondo, M.A. Avagnina, G. Recondo, V. Denninghoff
Journal: Journal of Thoracic Oncology (2017)
¿Existen « viejos » y « nuevos » métodos de detección de los riesgos y brotes de enfermedades infecciosas ?
Authors: J C Desenclos
Journal: Eurosurveillance (2006)

En mayo de 2005, la Asamblea mundial de la salud aprobo una revision innovadora y ambiciosa del Reglamento Sanitario Internacional (RSI, 2005), para detectar y controlar rapidamente todos los eventos de salud publica susceptibles de tener un impacto internacional importante. Esto representa un cambio brusco para los Estados Miembros (EM), y supone pasar de la notificacion administrativa de casos de una lista limitada de enfermedades a la Organizacion Mundial de la Salud (OMS), al analisis sistematico de eventos sanitarios de impacto internacional, sean o no infecciosos [1]. El analisis de estos eventos de salud publica tendra en cuenta la gravedad del mismo, su presentacion inesperada, el riesgo potencial de propagacion internacional, y las restricciones de los viajes y del comercio internacional. Es necesaria la identificacion en cada EM de puntos focales nacionales para la interaccion con la OMS. El principio del nuevo RSI es facilitar el dialogo entre los Estados Miembros y la OMS, con el fin de realizar una evaluacion rapida de los riesgos procedentes de eventos que no tienen porque ser automaticamente notificados, dependiendo de los resultados de la evaluacion y de las medidas adoptadas. La OMS tambien podra utilizar fuentes no oficiales para detectar mas rapidamente eventos de importancia internacional y entonces, con la colaboracion del punto focal nacional, llevar a cabo la comprobacion, la evaluacion de los riesgos y las medidas apropiadas.
Primer informe de vigilancia sobre Staphylococcus aureus resistentes a la meticilina adquiridos en la comunidad en Suiza
Authors: C Aramburu, S Harbarth, N Liassine, M Girard, A Gervaix, J Scherenzel, G Renzi, P Sudre
Journal: Eurosurveillance (2006)

Los SARM (Staphylococcus aureus resistentes a la meticilina) son un patogeno emergente en la comunidad. Los SARM adquiridos en la comunidad (CA-SARM) fueron asociados con cepas virulentas productores de leucocidina de Panton-Valentine (LPV) y varias otras exotoxinas. En Ginebra, tras la identificacion en 2002 del primer CA-SARM productor de LPV, se implanto un sistema de vigilancia basado en la declaracion voluntaria. 
Todos los cultivos positivos para SARM, con un perfil de resistencia a los antibioticos diferente de la cepa endemica prevalente en los centros de salud de Ginebra, diagnosticados en pacientes sin historia de hospitalizacion en los 12 meses previos, se declararon al departamento local de salud publica. El medico cumplimenta un cuestionario que contiene la informacion demografica, clinica y sobre la exposicion. 
Entre enero 2002 y diciembre 2004, fueron notificados 58 casos, de los cuales 26 estaban agrupados en 13 clusters epidemicos. La mayor parte de ellos pertenecian a la misma familia y en dos la colonizacion persistio durante mas de 12 meses, pese al tratamiento. Treinta y tres pacientes (el 57%) eran varones. La edad mediana fue de 32 anos y el 22% tenian menos de 10 anos. Cuarenta y un casos (71%) estaban infectados y 17 (29%) colonizados. De los 41 casos infectados, 40 presentaban lesiones dermatologicas sintomaticas, como forunculos, impetigo o un absceso. La mayoria de los pacientes no tenian enfermedades subyacentes. Treinta y ocho (65%) casos habian viajado al extranjero. Cuarenta (69%) de los aislamientos llevaban genes para la LPV.
P2.02-051 Bevacizumab Prevents Growth of Established Non-Small Cell Lung Cancer Brain Metastases in Hematogenous Brain Metastasis Model
Authors: C. Masuda, M. Monnai, C. Ishimaru, R. Nakamura, M. Kinoshita, K. Yorozu, M. Kurasawa, M. Sugimoto, K. Yamamoto
Journal: Journal of Thoracic Oncology (2017)
Abstract 20005: Cardiac Patients Risk Resuscitation Attempts Against Their Will Due to Lack of Do-Not-Resuscitate Conversations During Hospitalization
Authors: Camilla Bang, Ann K Sørensen, Camilla Hansen, Kasper G Lauridsen, Bo Løfgren
Journal: Circulation (2017)

Introduction: The decision to withhold resuscitation lies with the physician, but patients have the right to decline resuscitation. Many studies have shown that health professionals find Do-Not-Res...
MA 04.10 An Assessment of the Willingness to Provide Serial Bio-Specimens: Experience from an Irish Tertiary Cancer Centre
Authors: A. Baird, N. Keegan, M. Barr, S. Fishleder, A. Idris, E. Harrold, P. O'Kelly, E. Duff, S. Lim, M. O'Donnell, D. Gallagher, C. Grant, J. Kennedy, D. O'Donnell, S. Sukor, C. O'Brien, S. Finn, S. Cuffe
Journal: Journal of Thoracic Oncology (2017)
P1.01-013 Patient-Reported Outcomes and Safety from the Phase III ALUR Study of Alectinib vs Chemotherapy in Pre-Treated ALK+ NSCLC
Authors: J. Mazieres, S. Novello, J. De Castro, M.R. Migliorino, Å. Helland, R. Dziadziuszko, F. Griesinger, J. Wolf, A. Zeaiter, A. Cardona, B. Balas, T. Karagiannis, M. Chlistalla, V. Smoljanovic, I. Oh
Journal: Journal of Thoracic Oncology (2017)
Medical management of malignant bowel obstruction: our center experience
Authors: G. Astara, E. Lai, S. Tolu, R. Mascia, V. Impera, M. Dessì, S. Camera, G. Pusole, A. Cubeddu, A.G. Pireddu, N. Liscia, A. Pretta, L. Demurtas, P. Ziranu, M. Puzzoni, F. Atzori, V. Pusceddu, E. Massa, C. Madeddu, M. Scartozzi
Journal: Annals of Oncology (2017)
P1.01-011 Pattern of Care and Survival of ALK Rearranged Non-Small Cell Lung Cancer in Two Australian Referral Centers
Authors: M. Itchins, S. Kao, S. Hayes, V. Howell, A. Gill, W. Cooper, R. O'Connell, S. Clarke, N. Pavlakis
Journal: Journal of Thoracic Oncology (2017)
P1.14-005 Development of a Novel Spacer to Reduce Mediastinal Organ Toxicity from Stereotactic Body Radiotherapy
Authors: Y. Muranishi, T. Sato, M. Tanooka, H. Doi, Y. Yutaka, Y. Sakaguchi, S. Hasegawa, N. Kamikonya, T. Nakamura, H. Date
Journal: Journal of Thoracic Oncology (2017)
TMIC-10. TUMOR-ASSOCIATED NEUTROPHILS PROMOTE GLIOBLASTOMA GROWTH VIA OSTEOPONTIN IN A TARGETABLE MANNER
Authors: Garima Yagnik, Alan Nguyen, Soeren Mueller, Beatriz Alvarado, Payal Watchmaker, Arnold Kriegstein, Aaron Diaz, Manish K Aghi
Journal: Neuro-Oncology (2017)

While tumor-associated macrophages have been shown to exert pro-tumoral effects in glioblastoma, there is limited data on the function of tumor-associated neutrophils (TANs), particularly given their role in systemic inflammation. To characterize TANs, our lab isolated CD11b+ CD66b+ CD15+ TANs from patient gliomas (n=16) by FACS and performed single cell sequencing and functional assays examining neutrophil recruitment and downstream effects. TANs represented 1.4% (range=0.04-9.7%) of glioma cell suspensions. TANs increased as prognosis worsened: in high- vs. low-grade gliomas (2.2% vs. 0.3%, P=0.09), bevacizumab-resistant vs. naive GBMs (9.7% vs. 0.9%), and wildtype IDH1-R132 vs. mutant H132 variants (2.2% vs. 0.6%). Cultured bevacizumab-resistant and IDH1-R132 cells exhibit increased neutrophil chemotactic attraction (P<0.05) and increased levels of neutrophil chemoattractant leukotriene B4 (P<0.01) compared to bevacizumab-responsive and mutant IDH1-H132. TCGA analysis revealed higher levels of neutrophil marker myeloperoxidase in IDH1 wildtype vs. mutant GBMs (P<5x10-6). Principal component analysis of TAN single cell expression data elucidated novel candidate genes defining anti-tumoral N1 vs. pro-tumoral N2 subtypes: CCL20, SPARCL1, AKT2, FGF1, RAP2B, HMOX1, SPP1, FTL, PDGFD, and PDGFA. Reciprocal qPCRs of these genes in tumor cells and neutrophils cultured in conditioned media (CM) revealed osteopontin (SPP1) as a mediator of TAN-tumor crosstalk and a strong N2 protumoral candidate gene. Circulating neutrophils expressed no detectable SPP1, while TANs showed a three-fold increase in response to tumor cell CM. Tumor cells cultured in neutrophil CM demonstrated increased proliferation, which was eliminated with an osteopontin blocking antibody (P<0.01). Through reciprocal cross-talk, glioma cells recruit circulating neutrophils into tumors and convert them into a N2 pro-tumoral subtype, which in turn promote glioma cell proliferation and are associated with poor prognosis glioma types. Single cell sequencing identified genes defining potential N1/N2 subtypes, with osteopontin emerging as a potential therapeutic target to inhibit the pro-tumoral effects of TANs.
Gender and MGMT methylation in glioblastoma patients: interactions in the PERNO prospective study
Authors: E. Franceschi, A. Tosoni, R. Depenni, B. Urbini, M. Faedi, M. Michiara, C. Biasini, E. Giombelli, G. Pavesi, F. Zanelli, M.A. Cavallo, L. Tosatto, A. Fioravanti, E. Zunarelli, G. Lanza, D. Bartolini, E.M. Silini, A.A. Brandes
Journal: Annals of Oncology (2017)
P3.15-002 Molecular Profiling and Networks Relevant to Disease Mechanisms in Small Cell Lung Cancer and Lung Carcinoid Tumor
Authors: K. Fujii, Y. Miyata, I. Takahashi, H. Koizumi, H. Saji, M. Takagi, H. Nakamura, T. Nishimura
Journal: Journal of Thoracic Oncology (2017)
PUB059 Gefitinib Versus Pemetrexed-Platinum Therapy in EGFR Activating Mutated Lung Cancer: Impact on Brain Metastasis
Authors: K. Prabhash, V. Patil, A. Joshi, V. Noronha, N. Pande, A. Chandrasekaran, A. Mahajan, A. Janu
Journal: Journal of Thoracic Oncology (2017)
Nonacog Beta Pegol: A Review in Haemophilia B
Authors: Yahiya Y. Syed
Journal: Drugs (2017)

Nonacog beta pegol [Refixia® (EU)] is an intravenously-administered, glycoPEGylated recombinant factor IX (FIX), with an extended terminal half-life. It is approved in the EU for the treatment and prophylaxis of bleeding in patients aged ≥ 12 years with haemophilia B. The therapeutic efficacy and safety of nonacog beta pegol was demonstrated in the phase 3 Paradigm trials in previously treated adolescents and adults with haemophilia B. In Paradigm 2, nonacog beta pegol showed good haemostatic effects when treating bleeds on-demand, and reduced annualized bleeding rates when used as a once-weekly prophylaxis. It also improved some health-related quality of life measures in adult patients. The longer-term efficacy of nonacog beta pegol was demonstrated in the open-label extension Paradigm 4 trial. In Paradigm 3, nonacog beta pegol effectively maintained intraoperative and postoperative haemostasis. Nonacog beta pegol was well tolerated in phase 3 clinical trials in patients with haemophilia B, with no evidence of FIX inhibitor formation, allergic reactions or thromboembolic complications. In conclusion, nonacog beta pegol is effective and well tolerated in the on-demand, prophylaxis and perioperative settings in adolescent and adults with haemophilia B. Its extended half-life allows for once-weekly prophylaxis. Therefore, nonacog beta pegol is a useful additional treatment option for patients with haemophilia B.
Populações vulneráveis : as lições da onde de calor do verão 2003 na Europa
Authors: G Brücker
Journal: Eurosurveillance (2005)

Que licao podemos apprender da onda de calor, exceptionalmente longa e severa, que ocorreu na Europa em 2003? 
Primeiro, que estas ondas de calor podem provocar um excesso de mortalidade consideravel : mais de 50 000 obitos na Europa em Agosto de 2003. Provavelmente as consequencias foram subestimadas em muitos paises, ao menos nas primeiras avaliacoes. Este excesso de mortalidade afeta grupos vulneraveis, sobretudo pessoas idosas e doentes. A identificacao dos factores de risco e prioritaria si as indispensaveis acoes de prevencao devem ser implementadas.
Clinical use of immune-checkpoint inhibitors: focus on late immune-related adverse events and pseudoprogression
Authors: C. Sini, A.M. Carta, G. Bardino, E.M. Saba, A. Coinu, E. Defraia, S. Ortu, M.G. Schintu, T. Pira, B. Frau, G. Soru, A. Masale
Journal: Annals of Oncology (2017)
LibroBluApp: a mobile app to improve cancer care
Authors: I.G. Rapposelli, O. Fusco, P. Deligiannis, A. Pastorini, M.S. Fiumanò, E. Menatti, V. Viaggi, M. Volpi, F. Stiglich, T. Redaelli Spreafico, S. Slucca, A. Bertolini
Journal: Annals of Oncology (2017)
Abstract 20924: Threshold Based Infrared Imaging for Prevention of Esophageal Thermal Injury During Atrial Fibrillation Ablation
Authors: James Hummel, Anis Kadado, Matthew Baker, Murrium Sadaf, Anil Gehi, Paras Bhatt, Alan Enriquez, James Freeman, Mark Marieb, Paul Mounsey, Joseph G Akar
Journal: Circulation (2017)

Introduction: Cardiac ablation for atrial fibrillation has the potential to cause esophageal thermal injury. Thermocouple and thermistor-based systems are commonly used to monitor esophageal temperature at one or a few discrete locations, however, these systems have not eliminated thermal injuries and employ thresholds that are considerably lower than well-established temperatures required for irreversible tissue damage. Hypothesis: To mitigate esophageal thermal injury we modulated delivery of cardiac ablation energy using temperatures obtained from a high-resolution, intra-body, infrared thermography catheter that images esophageal temperatures. Methods: Esophageal temperatures were recorded from 28 patients undergoing pulmonary vein isolation using RF energy. An infrared catheter recorded surface temperatures from 7,680 points per second over a 6 cm length of esophagus. Physicians used a stepwise approach to set an esophageal temperature threshold. For initial cases a cutoff of 46 ° C was used and for subsequent cases the threshold was raised to a maximum value of 50 ° C. Full endoscopy was performed 1 to 3 days after the ablation procedure to document and quantify esophageal injury. Results: Posterior wall ablation resulted in 196 thermal elevations &gt;40 ° C (mean 7.0±4.2) and nearly all patients (27/28) experienced a peak esophageal temperature (T peak ) &gt;40 ° C. Eight patients experienced T peak &gt;50 ° C; with a maximum recorded T peak =53 ° C. T peak exceeded the programmed infrared temperature threshold in 12/28 patients. All patients received a full endoscopy. None of these temperature excursions resulted in visible thermal esophageal injury. Conclusions: Infrared thermography provided comprehensive monitoring of esophageal temperatures during ablation. By conventional metrics (e.g. Temperature&gt;40 ° C) a large number of thermal elevations were documented. However, infrared imaging provided instantaneous temperatures that allowed for limited interruption of ablation while preserving esophageal tissue integrity.
IMMU-57. STRATEGY TO ENHANCE DC MIGRATION FOR INCREASED EFFICACY OF DENDRITIC CELL VACCINE IMMUNOTHERAPY
Authors: Farhad Dastmalchi, Aida Karachi, Hassan Azari, Duane Mitchell, Maryam Rahman
Journal: Neuro-Oncology (2017)

Based on our previous publication in Nature, we have established that increasing dendritic cell (DC) migration in glioblastoma (GBM) patients treated with DC vaccination results in significantly improved survival. In this project we evaluated the efficacy of using a non-toxic, naturally occurring metabolite called sarcosine to increase cellular migration in the setting of cellular immunotherapy. In-vitro migration was analyzed with cytotoxic cell transfer membrane. In vivo migration was evaluated by vaccinating in a murine model. C57BL/6 mice received tetanus diphtheria (Td) toxoid vaccine prior to vaccination with DCs. After 48 hours post-vaccination, animals were culled for migration analysis of the dissociated lymph nodes through cytometry and immunofluorescence technique. This experiment was repeated to for spleen analysis as well. Sarcosine did not alter DC growth or phenotype. DCs loaded with sarcosine demonstrated significantly increased migration in vitro. Mice treated with DC vaccination in the setting of sarcosine demonstrated increased DCs migration to draining lymph nodes and spleens after 48 hours. The migration percentage of cells to the draining lymph nodes were 7.5%, 18.3% and 25.3% for regular DCs, sarcosine loaded DCs and sarcosine plus PKH loaded DCs respectively (p<0.05). All analyses showed migration of DCs was further enhanced when sarcosine combined with PKH staining. Sarcosine in combination with PKH increased antigen specific CD8 T cells after vaccination compared to regular DC vaccination. Sarcosine is non-toxic and significantly increases DC migration after vaccination resulting in a more robust immune response to vaccination. The effects of outcomes in a brain tumor model are ongoing.
GENE-57. REAPPRAISAL OF MOLECULAR/HISTOPATHOLOGICAL AND CLINICAL CHARACTERISTICS OF LOWER GRADE GLIOMAS
Authors: Eriel Sandika Pareira, Kentaro Ohara, Makoto Shibuya, Yu Nakagawa, Tokunori Kanazawa, Dai Kamamoto, Kazunari Yoshida, Hikaru Sasaki
Journal: Neuro-Oncology (2017)

There is a trend of shift on glioma histopathological diagnosis. In the revised 4th edition of WHO criteria in 2016, oligodendroglioma is defined by presence of 1p/19q codeletion. However, some tumors do not fit into any of the diagnostic categories. Diffuse gliomas lacking IDH mutation and 1p/19q codeletion that possess morphological characteristics of oligodendroglioma exist and molecular and clinical feature of such gliomas is still unclear. A hundred cases with diagnoses of grade II or III gliomas that underwent resection surgery (excluding biopsy) between 1990 and 2016 in a single institution were included. Two neuropathologists reevaluated the tumors independently based on HE specimens. After consensus diagnoses were met, the original diagnoses made by the institution in each era were compared with. Reassessment of histopathology (according to WHO 2007) was made with particular attention to the presence or absence of histologic features of CFO (classic for oligodendroglioma). Molecular genetic evaluation included metaphase CGH for chromosomal copy number aberrations, sequencing of IDH genes and TERT promoter region, immunohistochemistry of ATRX, and methylation-specific PCR of MGMT. Results of histopathological reassessment and molecular analyses were compared with survival outcomes. We found that there is a 70% of change in final diagnosis made by reassessment compared to the original diagnosis made by the institution, and most of the changes were either shift from grade II to grade III or from astrocytoma to oligodendroglioma/oligoastrocytoma. 1p/19q codeletion was found in 50% of tumors with consensus diagnoses of pure oligodendroglioma (grade II or III), and in 72% of tumors with CFO. There might be a trend of histological diagnoses of grade III and oligodendroglioma/oligoastrocytoma being more frequently made in current practice than before. Presence of CFO predicted 1p/19q codeletion better than histological diagnosis of oligodendroglioma. Results of molecular/genetic analyses in comparison to survival outcomes will be presented.
MA 07.07 Clinical Outcomes and ALK Resistance Mutations in ALK+ Non-Small Cell Lung Cancer According to EML4-ALK Variant
Authors: J. Lin, V. Zhu, S. Yoda, B. Yeap, N. Jessop, A. Schrock, I. Dagogo-Jack, K. Gowen, P.J. Stephens, J. Ross, S. Ali, V. Miller, J. Gainor, A. Hata, A. Iafrate, S. Ou, A. Shaw
Journal: Journal of Thoracic Oncology (2017)
P3.08-001 Concurrent Chemoradiotherapy with Weekly Carboplatin-Paclitaxel May Be Feasible Option in inoperable Stage III NSCLC
Authors: Z. Calikusu, G. Ugurluer, M. Serin, A.M. Sedef, H. Mertsoylu, A. Besen, F. Kose
Journal: Journal of Thoracic Oncology (2017)
P3.02-045 Prevalence of ALK Gene Abnormalities in Routine Diagnostics of Polish NSCLC Patients
Authors: A. Grenda, P. Krawczyk, K. Wojas-Krawczyk, T. Kucharczyk, B. Jarosz, K. Reszka, J. Pankowski, A. Szlubowski, J. Buczkowski, A. Szczęsna, B. Kuźniar-Kamińska, K. Siemiątkowska, J. Kołb-Sielecki, W. Papiewski, J. Milanowski
Journal: Journal of Thoracic Oncology (2017)